Amyotrophic lateral sclerosis (ALS) is a fatal upper and lower motor neuron degradation disease that leads to progressive myofiber abnormalities (e.g. decreased size and distribution). With recently FDA-cleared treatments, it is critical to identify non-invasive biomarkers of early disease onset, progression and therapy response. In this study, we validate the potential of a recently developed MR Cytography approach to detect myofiber microstructural changes in an ALS mouse model over three time points by comparison to relevant histologic markers.
This abstract and the presentation materials are available to members only; a login is required.